Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D I Jodrell

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancerD I Jodrell, M J Egorin, R M Canetta, et al.
Cancer Research|June 26, 1999
Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancerK C Connolly, H Gabra, C J Millwater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancerL M Reyno, M J Egorin, R M Canetta, et al.
Seminars in Oncology|October 1, 1994
Modeling toxicity and response in carboplatin-based combination chemotherapyM J Egorin, L M Reyno, R M Canetta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancerD I Jodrell, L M Reyno, R Sridhara, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8- dideazafolate as antitumour agentsA L Jackman, G M Bisset, D I Jodrell, et al.
Journal of the National Cancer Institute|April 21, 1993
Suramin, an active drug for prostate cancer: interim observations in a phase I trialM A Eisenberger, L M Reyno, D I Jodrell, et al.
British Journal of Cancer|July 4, 1998
Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalationM J Mackean, J Cassidy, D I Jodrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancerM A Eisenberger, V J Sinibaldi, L M Reyno, et al.
Journal of Medicinal Chemistry|October 19, 2001
Inhibition of cancer cell growth by ruthenium(II) arene complexesR E Morris, R E Aird, P del S Murdoch, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancerD I Jodrell, M J Egorin, R M Canetta, et al.
Cancer Research|June 26, 1999
Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancerK C Connolly, H Gabra, C J Millwater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancerL M Reyno, M J Egorin, R M Canetta, et al.
Seminars in Oncology|October 1, 1994
Modeling toxicity and response in carboplatin-based combination chemotherapyM J Egorin, L M Reyno, R M Canetta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancerD I Jodrell, L M Reyno, R Sridhara, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8- dideazafolate as antitumour agentsA L Jackman, G M Bisset, D I Jodrell, et al.
Journal of the National Cancer Institute|April 21, 1993
Suramin, an active drug for prostate cancer: interim observations in a phase I trialM A Eisenberger, L M Reyno, D I Jodrell, et al.
British Journal of Cancer|July 4, 1998
Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalationM J Mackean, J Cassidy, D I Jodrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancerM A Eisenberger, V J Sinibaldi, L M Reyno, et al.
Journal of Medicinal Chemistry|October 19, 2001
Inhibition of cancer cell growth by ruthenium(II) arene complexesR E Morris, R E Aird, P del S Murdoch, et al.
Pageof 6